StockData

Amneal Pharmaceuticals vs Phibro Animal Health

AMRX and PAHC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMRX and PAHC compare

Amneal Pharmaceuticals is the larger company, worth 4.8 times as much as Phibro Animal Health ($6.8B against $1.4B).

On earnings, Phibro Animal Health is cheaper: it trades at 14.4× trailing earnings, against 43.3× for Amneal Pharmaceuticals.

Phibro Animal Health grew revenue faster over the last twelve months (17.1% versus 9.3% for Amneal Pharmaceuticals).

Phibro Animal Health keeps more of each dollar of sales as profit, with a net margin of 6.6% compared with 5.0% at Amneal Pharmaceuticals.

Phibro Animal Health pays a dividend yielding 1.4%; Amneal Pharmaceuticals does not pay one.

Phibro Animal Health scores higher on the StockData Score (22 against 10 for Amneal Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMRXPAHC
Size and price
Market cap$6.8B$1.4B
Share price$21.23$35.02
Change, 1 year84.3%−21.7%
Change, 5 years400%67.7%
Beta (5Y)0.90−0.07
Employees8,5002,605
StockData Score
Total score1022 (better)
Valuation score05 (better)
Growth score56 (better)
Performance score46 (better)
Health score12 (better)
Dividend score03 (better)
Valuation
P/E43.3×14.4× (better)
P/S2.2×0.9× (better)
P/B205×3.7× (better)
EV/EBITDA20.3×5.4× (better)
P/FCF53.0× (better)144×
PEG–0.33
FCF yield1.9% (better)0.69%
Fair value$13.07$65.45
Margin of safety−62.4%46.5% (better)
Growth
Revenue growth (TTM)9.3%17.1% (better)
Revenue growth, 5Y average8.7%12.7% (better)
Net income growth (TTM)4563% (better)107%
EPS growth (TTM)4800% (better)104%
EPS growth, 5Y average−18.5%12.6% (better)
Profitability
Gross margin39.3% (better)33.8%
Operating margin14.6% (better)12.8%
Net margin5.0%6.6% (better)
FCF margin4.1% (better)0.65%
Return on equity–29.7%
Return on invested capital20.3%24.7% (better)
Financial health
Debt / equity77.83–
Net debt / EBITDA5.38–
Interest coverage–4.2×
Current ratio2.202.96 (better)
Altman Z-score2.493.03 (better)
Piotroski F-score7 (better)6
Dividends and buybacks
Dividend yield–1.4%
Payout ratio–19.5%
Years of dividend growth–0
Dividend growth, 5Y average–0.00%
Shareholder yield0.00%1.4% (better)
Ownership
Held by institutions52.7%51.8%
Held by insiders60.7%98.9%
Insider net buying, 12 months−$7.7M (better)−$23.0M
Short interest, % of float9.1%233%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.